{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:05Z","timestamp":1787020745739,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with maple syrup urine disease (MSUD) experiencing metabolic decompensations have traditionally been treated with branched-chain amino acid (BCAA)-free mixture via oral or nasogastric administration routes. In some patients, enteral administration is not possible, either because the patient presents with vomiting, coma, or refuses nasogastric administration, thus intravenous (IV) BCAA-free solution is an appropriate intervention for these challenging cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study aimed to evaluate the effectiveness and safety of managing metabolic decompensations by administering an IV BCAA-free solution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is an observational prospective study of data from MSUD patients hospitalised for decompensation episodes between 2010 and 2016 at 6 centres for rare metabolic diseases in France.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 24 patients (16 males; 8 females) experiencing 126 MSUD metabolic decompensation episodes (39 in children; 87 in adults) were admitted to hospital. At presentation, mean leucine plasma concentration was \u2265\u2009381\u00a0\u00b5mol\/L in 113\/126 (89.7%) episodes. Children were treated with continuous IV BCAA-free solution at doses of 0.8 to 2.0\u00a0g\/kg\/day, for 4.8\u00a0days and adults for 3.8\u00a0days at doses of 0.5 to 2.6\u00a0g\/kg\/day. In the efficacy set of 102 analysable episodes leucine concentrations were normalised (to below 381\u00a0\u00b5mol\/L) in 82% (n\u2009=\u200918\/22) of episodes in children and in 84% (n\u2009=\u200967\/80) of episodes in adults. Mean time to leucine normalisation was 3.0\u00a0days. This was significantly (p\u2009&lt;\u20090.001) shorter than the algorithmically predicted time to leucine normalisation with traditional BCAA-free mixture. Duration of hospitalisation was significantly longer for children than for adults (7.1\u00a0days in children vs 5.2\u00a0days in adults, p\u2009=\u20090.012). No treatment-related adverse events were reported in any patients on IV BCAA-free solution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The IV BCAA-free solution is safe and effective in normalising leucine concentrations during MSUD decompensation episodes in both children and adults, offering a practical treatment alternative for those patients who cannot receive BCAA-free mixture via oral or nasogastric routes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-022-02353-2","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T08:03:12Z","timestamp":1652688192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intravenous administration of a branched-chain amino-acid-free solution in children and adults with acute decompensation of maple syrup urine disease: a prospective multicentre observational study"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3988-5494","authenticated-orcid":false,"given":"Jean-Meidi","family":"Alili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Berleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Caroline","family":"Husson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Mention","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Arnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Brassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Guemman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coraline","family":"Grisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Th\u00e9r\u00e8se","family":"Abi-Ward\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Broissand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"de Lonlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"2353_CR1","unstructured":"Hassan SA, Gupta V. Maple syrup urine disease. StatPearls. Treasure Island (FL): StatPearls Publishing; 2021."},{"key":"2353_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ymgmr.2018.03.011","volume":"15","author":"KA Chapman","year":"2018","unstructured":"Chapman KA, Gramer G, Viall S, Summar ML. Incidence of maple syrup urine disease, propionic acidemia, and methylmalonic aciduria from newborn screening data. Mol Genet Metab Rep. 2018;15:106\u20139.","journal-title":"Mol Genet Metab Rep"},{"key":"2353_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10238-016-0435-0","volume":"17","author":"GR Villani","year":"2017","unstructured":"Villani GR, Gallo G, Scolamiero E, Salvatore F, Ruoppolo M. \u201cClassical organic acidurias\u201d: diagnosis and pathogenesis. Clin Exp Med. 2017;17:305\u201323.","journal-title":"Clin Exp Med"},{"key":"2353_CR4","doi-asserted-by":"publisher","first-page":"7490","DOI":"10.3390\/ijms21207490","volume":"21","author":"J Xu","year":"2020","unstructured":"Xu J, Jakher Y, Ahrens-Nicklas RC. Brain branched-chain amino acids in maple syrup urine disease: implications for neurological disorders. Int J Mol Sci. 2020;21:7490.","journal-title":"Int J Mol Sci"},{"key":"2353_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/TACG.S125962","volume":"10","author":"PR Blackburn","year":"2017","unstructured":"Blackburn PR, Gass JM, Vairo FPE, et al. Maple syrup urine disease: mechanisms and management. Appl Clin Genet. 2017;10:57\u201366.","journal-title":"Appl Clin Genet"},{"key":"2353_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ymgme.2020.01.006","volume":"129","author":"KA Strauss","year":"2020","unstructured":"Strauss KA, Carson VJ, Soltys K, et al. Branched-chain \u03b1-ketoacid dehydrogenase deficiency (maple syrup urine disease): treatment, biomarkers, and outcomes. Mol Genet Metab. 2020;129:193\u2013206.","journal-title":"Mol Genet Metab"},{"key":"2353_CR7","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/jimd.12337","volume":"44","author":"D O\u2019Reilly","year":"2021","unstructured":"O\u2019Reilly D, Crushell E, Hughes J, et al. Maple syrup urine disease: clinical outcomes, metabolic control, and genotypes in a screened population after four decades of newborn bloodspot screening in the Republic of Ireland. J Inherit Metab Dis. 2021;44:639\u201355.","journal-title":"J Inherit Metab Dis"},{"key":"2353_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/978-2-8178-0046-2","volume-title":"Prise en charge m\u00e9dicale et di\u00e9t\u00e9tique des maladies h\u00e9r\u00e9ditaires du m\u00e9tabolisme","author":"P de Lonlay","year":"2013","unstructured":"de Lonlay P, Dubois S, Valayannopoulos V, Depondt E, Ottolenghi C, Rabier D. Prise en charge m\u00e9dicale et di\u00e9t\u00e9tique des maladies h\u00e9r\u00e9ditaires du m\u00e9tabolisme. 1st ed. Paris: Springer; 2013.","edition":"1"},{"key":"2353_CR9","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00431-020-03602-x","volume":"179","author":"Y Y\u0131ld\u0131z","year":"2020","unstructured":"Y\u0131ld\u0131z Y, Akcan Y\u0131ld\u0131z L, Dursun A, et al. Predictors of acute metabolic decompensation in children with maple syrup urine disease at the emergency department. Eur J Pediatr. 2020;179:1107\u201314.","journal-title":"Eur J Pediatr"},{"key":"2353_CR10","doi-asserted-by":"publisher","first-page":"100763","DOI":"10.1016\/j.ymgmr.2021.100763","volume":"27","author":"L Guilder","year":"2021","unstructured":"Guilder L, Prada CE, Saenz S, et al. Hyperleucinosis during infections in maple syrup urine disease post liver transplantation. Mol Genet Metab Rep. 2021;27:100763.","journal-title":"Mol Genet Metab Rep"},{"key":"2353_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ymgme.2014.05.006","volume":"112","author":"DM Frazier","year":"2014","unstructured":"Frazier DM, Allgeier C, Homer C, et al. Nutrition management guideline for maple syrup urine disease: an evidence- and consensus-based approach. Mol Genet Metab. 2014;112:210\u20137.","journal-title":"Mol Genet Metab"},{"key":"2353_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/PEC.0000000000001299","volume":"34","author":"LH Rodan","year":"2018","unstructured":"Rodan LH, Aldubayan SH, Berry GT, Levy HL. Acute illness protocol for maple syrup urine disease. Pediatr Emerg Care. 2018;34:64\u20137.","journal-title":"Pediatr Emerg Care"},{"key":"2353_CR13","doi-asserted-by":"publisher","first-page":"100655","DOI":"10.1016\/j.ymgmr.2020.100655","volume":"26","author":"CM B\u00e9rat","year":"2021","unstructured":"B\u00e9rat CM, Roda C, Brassier A, et al. Enteral tube feeding in patients receiving dietary treatment for metabolic diseases: a retrospective analysis in a large French cohort. Mol Genet Metab Rep. 2021;26:100655.","journal-title":"Mol Genet Metab Rep"},{"key":"2353_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ymgme.2017.09.012","volume":"122","author":"AI Scott","year":"2017","unstructured":"Scott AI, Cusmano-Ozog K, Enns GM, Cowan TM. Correction of hyperleucinemia in MSUD patients on leucine-free dietary therapy. Mol Genet Metab. 2017;122:156\u20139.","journal-title":"Mol Genet Metab"},{"key":"2353_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1542\/peds.92.2.280","volume":"92","author":"R Parini","year":"1993","unstructured":"Parini R, Sereni LP, Bagozzi DC, et al. Nasogastric drip feeding as the only treatment of neonatal maple syrup urine disease. Pediatrics. 1993;92:280\u20133.","journal-title":"Pediatrics"},{"key":"2353_CR16","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s10545-012-9570-2","volume":"36","author":"A Servais","year":"2013","unstructured":"Servais A, Arnoux JB, Lamy C, et al. Treatment of acute decompensation of maple syrup urine disease in adult patients with a new parenteral amino-acid mixture. J Inherit Metab Dis. 2013;36:939\u201344.","journal-title":"J Inherit Metab Dis"},{"key":"2353_CR17","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10545-017-0083-x","volume":"40","author":"MT Abi-Ward\u00e9","year":"2017","unstructured":"Abi-Ward\u00e9 MT, Roda C, Arnoux JB, et al. Long-term metabolic follow-up and clinical outcome of 35 patients with maple syrup urine disease. J Inherit Metab Dis. 2017;40:783\u201392.","journal-title":"J Inherit Metab Dis"},{"key":"2353_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.24953\/turkjped.2019.01.017","volume":"61","author":"F Ayg\u00fcn","year":"2019","unstructured":"Ayg\u00fcn F, K\u0131yk\u0131m E, Aktu\u011flu-Zeybek \u00c7, Zubario\u011flu T, Cam H. Treatment of maple syrup urine disease with high flow hemodialysis in a neonate. Turk J Pediatr. 2019;61:107\u201310.","journal-title":"Turk J Pediatr"},{"key":"2353_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1046\/j.1442-200X.1999.4121044.x","volume":"41","author":"M Yoshino","year":"1999","unstructured":"Yoshino M, Aoki K, Akeda H, et al. Management of acute metabolic decompensation in maple syrup urine disease: a multi-center study. Pediatr Int. 1999;41:132\u20137.","journal-title":"Pediatr Int"},{"key":"2353_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/jmd2.12207","volume":"59","author":"P de Lonlay","year":"2021","unstructured":"de Lonlay P, Posset R, M\u00fctze U, et al. Real-world management of maple syrup urine disease (MSUD) metabolic decompensations with branched chain amino acid-free formulas in France and Germany: a retrospective observational study. JIMD Rep. 2021;59:110\u20139.","journal-title":"JIMD Rep"},{"key":"2353_CR21","first-page":"S38","volume":"38","author":"JM Alili","year":"2015","unstructured":"Alili JM, Martin C, Amchin L, et al. Intravenous administration of a specific amino-acid mixture in children and adults with acute decompensation of maple syrup urine disease: a prospective observational study. J Inherit Metab Dis. 2015;38:S38.","journal-title":"J Inherit Metab Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02353-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02353-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02353-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T08:09:22Z","timestamp":1652688562000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02353-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2353"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02353-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"assertion":[{"value":"8 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this was a non-interventional study, patient consent was not required. As per French legal requirements all patients or their parents\/caregivers were informed of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"As this was a non-interventional study, patient consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Drs Jean-Meidi Alili, Marie-Pierre Berleur and Marie-Caroline Husson work or used to work in the French public institution, Pharmaceutical Establishment of Paris Hospitals (<i>AGEPS<\/i>) that distributed the IV BCAA-free solution in France as a hospital preparation. The other authors declare having no particular conflicts of interest with regard to this research or their contributions to this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"202"}}